Ecraid Joins the PrIMAVeRa Consortium to Accelerate Antimicrobial Resistance Modelling
Ecraid is delighted to announce that we’ve joined the PrIMAVeRa (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) consortium! This partnership marks a strategic alignment between our established, high-capacity clinical research network and PrIMAVeRa's mission to model the impact of novel interventions on AMR.
Established in 2022 as the first European network offering a single point of access to a pan-European clinical research infrastructure for infectious diseases, Ecraid’s core mission is to improve clinical evidence in the fight against infectious diseases and AMR. By joining the PrIMAVeRa consortium, Ecraid will not only provide valuable scientific analysis but, critically, will offer direct access to participant-level data essential for refining mathematical models.
The Value of Ecraid's Perpetual Observational Studies (POS)
The most significant contribution Ecraid brings to the consortium is the wealth of real-world data generated by our Perpetual Observational Studies (POS). These studies are designed to continually enrol patients and collect prospective, standardised data across our pan-European network, ensuring both scale and consistency.
The data provided to PrIMAVeRa will be drawn from our key POS focused on severe infections: complicated urinary tract infections (POS-cUTI) and ventilator-associated pneumonia (POS-VAP). As a testament to the network’s scalability, the two POS have now enrolled over 12,000 patients, providing a robust and detailed dataset.
This extensive data is uniquely positioned to fill critical gaps previously identified by modellers, offering insights into:
- Infection outcomes, rigorously stratified according to antibiotic susceptibilities.
- Details on implemented therapies and their duration.
- Associated hospital resource consumption metrics.
Accelerating the Fight Against AMR
This detailed, participant-level information is vital. It will be used to train and refine the sophisticated mathematical models being developed by the PrIMAVeRa consortium. The objective is to accurately demonstrate the true clinical and economic impact of prophylactic measures, specifically vaccines and mAbs, on curbing AMR development.
Ecraid’s involvement ensures that these crucial models are grounded in the highest quality, most relevant European clinical data available.
We look forward to a successful collaboration with our new partners, reinforcing the collective effort in the ongoing fight against AMR, and ensuring that our operational capability is directly leveraged to inform global public health policy.
